Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Varzicar is an oral neuro-nutritional dietary supplement developed and marketed by Primus Remedies. It is formulated to support brain development, cognitive function, and overall neurological health, particularly in children. Varzicar is available in two main formulations: a syrup containing L-carnosine, docosahexaenoic acid (DHA), coenzyme Q10 (CoQ10), vitamin A, vitamin D3, and cyanocobalamin (vitamin B12); and tablets containing L-carnosine, coenzyme Q10, adenosine monophosphate (AMP), and vitamin D. The combination of these active ingredients provides antioxidant protection, supports mitochondrial energy production, and promotes neuronal growth and synaptic connectivity. It is commonly used as supportive nutritional therapy for neurodevelopmental conditions such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), speech delay, and general developmental delays.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Varzicar.